Search for: "Boehringer Ingelheim Pharmaceuticals"
Results 121 - 140
of 252
Sorted by Relevance
|
Sort by Date
9 Aug 2012, 12:58 pm
Pradaxa (dabigitran) is an anticoagulant that was released by Boehringer Ingelheim in October 2010 for prevention of strokes in patients with non-valvular atrial fibrillation. [read post]
9 Aug 2012, 12:58 pm
Pradaxa (dabigitran) is an anticoagulant that was released by Boehringer Ingelheim in October 2010 for prevention of strokes in patients with non-valvular atrial fibrillation. [read post]
30 Apr 2012, 1:02 pm
Pradaxa is a medication manufactured by Boehringer-Ingelheim Pharmaceuticals to help patients who have a higher risk of stroke, but the reported side effects, if proven to be true, create dangers that outweigh the benefits for those who use it. [read post]
15 Jul 2011, 7:40 am
Tiotropium bromide capsules for inhalation are co-promoted by Boehringer-Ingelheim and Pfizer under the trade name Spiriva. [read post]
1 Dec 2009, 9:45 am
Intervet Inc. and Boehringer Ingelheim Vetmedica, Inc. [read post]
30 Jun 2016, 12:12 pm
“For dabigatran [Pradaxa, Boehringer Ingelheim]-treated patients, idarucizumab [Praxbind, Boehringer Ingelheim], a monoclonal antibody that binds dabigatran and acutely reverses its anticoagulation effect, is currently approved for major bleeding or for patients requiring emergency procedures, and is available in many countries,” Levy and Hunt wrote. [read post]
19 May 2009, 8:30 am
By 2005, 9 of the top 15 were based in the US and only one - Boehringer-Ingelheim - was in Germany. [read post]
5 May 2010, 4:46 am
Cyclacel Pharmaceuticals Inc. [read post]
15 Sep 2014, 1:46 pm
Pradaxa is a competitor blood thinner from Boehringer Ingelheim. [read post]
4 May 2013, 10:13 am
Tradjenta (linagliptin) is manufactured by Eli Lilly and Boehringer Ingelheim and approved for sale in 2011. [read post]
26 Jun 2011, 8:00 pm
Facts Lynda Kerr was hired by Boehringer in July 1996 as a pharmaceutical sales representative. [read post]
10 Jun 2015, 11:51 am
This class of drugs consists of: Invokana — Janssen Pharmaceuticals — FDA Approval: 2013Invokamet — Janssen Pharmaceuticals — FDA Approval: 2014Farxiga — AstraZeneca Pharmaceuticals — FDA Approval: 2014Xigduo XR — AstraZeneca Pharmaceuticals — FDA Approval: 2014Jardiance — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2014Glyxambi — Boehringer… [read post]
9 Mar 2009, 7:00 am
Skylight Studios275 Hudson Street, NYC7 pm - 10 pmPURCHASE TICKETS Participating chefs Anne BurrellThe Food Network Anita LoAnnisa Pichet OngP*ONG Suvir SaranDevi Lawrence Benenson Fiona and Stanley Druckenmiller Leslie Fay Pomerantz Anita Jaffe Bloomberg Davis Polk & Wardwell Jeffrey FashionCares 2009 May and Samuel Rudin Family Foundation Sonnenschein Nath &… [read post]
30 Jan 2020, 5:29 am
The Zantac litigation effort involves several international drug companies, including Boehringer Ingelheim Pharmaceuticals (based in Connecticut); Boehringer Ingelheim Corporation (German parent company); Sanofi US Services, Inc. [read post]
30 Jan 2020, 5:29 am
The Zantac litigation effort involves several international drug companies, including Boehringer Ingelheim Pharmaceuticals (based in Connecticut); Boehringer Ingelheim Corporation (German parent company); Sanofi US Services, Inc. [read post]
8 Nov 2007, 9:00 pm
Due to popular demand, I will have a separate section for Pharmaceutical Industry items from this week. [read post]
12 Mar 2015, 11:09 am
Today's the day that many pharmaceutical patent term extension-watchers have been waiting for with feelings of optimism or anxiety: the day on which the Court of Justice of the European Union (CJEU) delivered its ruling in Case C‑577/13, Actavis Group PTC EHF, Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. [read post]
23 Oct 2014, 3:27 pm
In the U.S., the drug industry spent $3.5 billion promoting its wares to consumers in 2012; in 2011, one manufacturer, Boehringer Ingelheim, spent $464 million advertising its blood thinner Pradaxa, a drug with demonstrable problems that have created legal problems for the company and considerable harm to patients. [read post]
22 Dec 2015, 7:03 am
On the eve of trial, Boehringer Ingelheim agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim. [read post]
24 Dec 2015, 6:43 am
On the eve of trial, Boehringer Ingelheim agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim. [read post]
